RELEASE: Celularity is proud to announce a U.S. manufacturing collaboration with MuseCell Innovations® to support the Dezawa MuseCell® platform at our Florham Park, New Jersey facility. businesswire.com/news/home/2… #CellularMedicine #Biomanufacturing #MuseCells

RELEASE: Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law Read the full release here: globenewswire.com/news-relea…

RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics. Read the full release here: globenewswire.com/news-relea…

RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses Read the full release here: globenewswire.com/news-relea…

RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz. globenewswire.com/news-relea…

RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. globenewswire.com/news-relea…

RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision READ THE FULL RELEASE HERE: globenewswire.com/news-relea…

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions. Read the full release here: globenewswire.com/news-relea…

Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease. Read the full release here: globenewswire.com/news-relea…

We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million senior secured debt. Read the full release here: globenewswire.com/news-relea…

We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses. globenewswire.com/news-relea…

RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law Read it here: globenewswire.com/news-relea…

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies globenewswire.com/news-relea…

Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. globenewswire.com/news-relea…

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products Read the full release here: globenewswire.com/news-relea…

An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer. Read the full release - with link to the publication - here: globenewswire.com/news-relea…